Insider Selling: Juno Therapeutics Inc (JUNO) EVP Sells $311,912.94 in Stock
Juno Therapeutics Inc (NASDAQ:JUNO) EVP Robert Azelby sold 12,921 shares of the firm’s stock in a transaction dated Thursday, November 10th. The stock was sold at an average price of $24.14, for a total transaction of $311,912.94. Following the completion of the transaction, the executive vice president now owns 48,640 shares in the company, valued at $1,174,169.60. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Shares of Juno Therapeutics Inc (NASDAQ:JUNO) opened at 32.97 on Tuesday. Juno Therapeutics Inc has a 52-week low of $22.37 and a 52-week high of $57.82. The firm’s 50 day moving average is $27.91 and its 200-day moving average is $33.47. The company’s market capitalization is $3.38 billion.
Juno Therapeutics (NASDAQ:JUNO) last announced its quarterly earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by $0.05. The business had revenue of $20.80 million for the quarter, compared to analysts’ expectations of $10.98 million. Juno Therapeutics’s revenue for the quarter was up 1200.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.26) earnings per share. Equities research analysts anticipate that Juno Therapeutics Inc will post ($2.45) earnings per share for the current fiscal year.
Several analysts recently weighed in on JUNO shares. Maxim Group reiterated a “buy” rating and issued a $80.00 price objective on shares of Juno Therapeutics in a research report on Monday, July 18th. BTIG Research started coverage on shares of Juno Therapeutics in a research report on Tuesday, August 30th. They issued a “sell” rating and a $23.00 price objective on the stock. Vetr downgraded shares of Juno Therapeutics from a “strong-buy” rating to a “buy” rating and set a $38.02 price objective on the stock. in a research report on Monday, August 22nd. Leerink Swann reiterated an “outperform” rating and issued a $45.00 price objective on shares of Juno Therapeutics in a research report on Tuesday, September 27th. Finally, Zacks Investment Research upgraded shares of Juno Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, September 6th. Five equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $46.27.
Large investors have recently made changes to their positions in the stock. TIAA CREF Investment Management LLC raised its stake in shares of Juno Therapeutics by 4.4% in the first quarter. TIAA CREF Investment Management LLC now owns 175,882 shares of the biopharmaceutical company’s stock valued at $6,699,000 after buying an additional 7,357 shares during the period. BlackRock Group LTD raised its stake in shares of Juno Therapeutics by 15.3% in the first quarter. BlackRock Group LTD now owns 34,653 shares of the biopharmaceutical company’s stock valued at $1,320,000 after buying an additional 4,609 shares during the period. BlackRock Fund Advisors raised its stake in shares of Juno Therapeutics by 14.1% in the first quarter. BlackRock Fund Advisors now owns 1,517,425 shares of the biopharmaceutical company’s stock valued at $57,799,000 after buying an additional 187,826 shares during the period. State Street Corp raised its stake in shares of Juno Therapeutics by 20.8% in the first quarter. State Street Corp now owns 1,218,468 shares of the biopharmaceutical company’s stock valued at $46,412,000 after buying an additional 210,019 shares during the period. Finally, Riverhead Capital Management LLC acquired a new stake in shares of Juno Therapeutics during the first quarter valued at about $2,845,000.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Stock Ratings for Juno Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc and related stocks with our FREE daily email newsletter.